Prediction and benefits of minimal disease activity in patients with psoriatic arthritis and active skin disease in the ADEPT trial

OBJECTIVES: To determine the proportion of patients with psoriatic arthritis in the Adalimumab Effectiveness in Psoriatic Arthritis trial achieving minimal disease activity (MDA) and its individual components at 1 or more visits over 144 weeks, identify baseline predictors of MDA achievement, and ev...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:RMD Open
Autores principales: Mease, Philip J, Kavanaugh, Arthur, Coates, Laura C, McInnes, Iain B, Hojnik, Maja, Zhang, Ying, Anderson, Jaclyn K, Dorr, Alexander P, Gladman, Dafna D
Formato: Artigo
Lenguaje:Inglês
Publicado: BMJ Publishing Group 2017
Materias:
Psoriatic Arthritis
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5708306/
https://ncbi.nlm.nih.gov/pubmed/29225916
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/rmdopen-2016-000415
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares